# p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

Source: https://onco.cc/trials/nct03268382/  
OnCo record `nct03268382` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Eprenetapopt and Pegylated liposomal doxorubicin in Ovarian cancer, run by Aprea Therapeutics, completed.

## Summary

p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 is a phase 2 interventional study registered as NCT03268382 by Aprea Therapeutics, with 36 participants recorded, started 2017-07-31 and reaching its primary completion in 2019-07-10. Interventions recorded: APR-246, Pegylated Liposomal Doxorubicin Hydrochloride (PLD). Conditions recorded: High-grade Serous Ovarian Cancer.

Linked to the idea "Is aneuploidy itself a druggable vulnerability?" because the registry names Eprenetapopt and Pegylated liposomal doxorubicin among its interventions and Ovarian cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03268382
- Phase: 2
- Setting: PiSARRO-R: p53 Suppressor Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Phase II Study of Systemic Pegylated Liposomal Doxorubicin Chemotherapy With APR-246
- Sponsor: Aprea Therapeutics
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT03268382: https://clinicaltrials.gov/study/NCT03268382

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Eprenetapopt](https://onco.cc/drugs/eprenetapopt/), [Pegylated liposomal doxorubicin](https://onco.cc/drugs/pegylated-liposomal-doxorubicin/)
- companies: [Aprea Therapeutics](https://onco.cc/companies/aprea-therapeutics/)
- ideas: [Is aneuploidy itself a druggable vulnerability?](https://onco.cc/ideas/idea-targeting-aneuploidy/)

---
JSON: https://onco.cc/api/v1/entities/nct03268382.json